Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that members of its management team will participate in two investor conferences in August and September 2026. President and Chief Executive Officer Dr. Seth Lederman will take part in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Aug. 11 from 1:30 p.m. to 1:55 p.m. ET. The company also said Lederman will participate in one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Sept. 16. These events provide Tonix an opportunity to discuss its business and engage with the investment community.
The announcements come as Tonix continues to build momentum following the recent approval of TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years. The company's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease.
Beyond CNS, Tonix is advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These initiatives underscore the company's focus on addressing areas of high unmet medical need.
The participation in these conferences is a strategic move to enhance visibility among investors and communicate the company's progress and future plans. With a fully integrated commercial-stage biotechnology platform, Tonix is well-positioned to capitalize on its recent achievements and drive shareholder value.
For more details on the conferences and Tonix's developments, visit the company's newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/DKFAC.
